Loading stock data…
Avalo Therapeutics, Inc. (AVTX)
$19.29+1.09 (+5.99%)
Market ClosedLast close Jun 29
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Avalo Therapeutics, Inc. in the Healthcare sector is trading at $19.29 with a market capitalization of $722M. Wall Street consensus targets $45.25 (12 analysts), implying a +134.6% move over the next 12 months. The stock is currently 21% below its 52-week high of $24.27, remaining 22.3% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +134.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $59,000 | $0 | $0 | $0 |
| Gross Profit | — | $59,000 | $0 | $0 | $0 |
| Operating Income | -$20.90M↓ | -$19.74M↓ | -$19.20M↑ | -$19.32M↓ | -$14.67M |
| Net Income | -$19.63M↓ | -$13.72M↑ | -$30.63M↓ | -$20.77M↓ | -$13.15M |
Peer Comparison
JNJUNHPFE
Fundamentals
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$722.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.79
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-124.03%
Volume
Today's trading volume
1.57M
Recent News
Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Additions - What's Changed
Avalo Therapeutics was recently added to a broad range of Russell indices, including the Russell 2000, 2500, 3000 and related growth, value and small-cap benchmarks, following index reconstitutions completed in June 2026. This unusually wide index inclusion amplifies Avalo’s visibility across both growth and value investor segments, potentially reshaping how the market views its emerging immunology pipeline. With recent gains and expanded Russell index membership as a backdrop, we’ll assess...
Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026
Avalo Therapeutics, Inc. (NASDAQ:AVTX) is among the best low priced stocks to get rich in 2026. On June 12, BofA started coverage on Avalo Therapeutics, Inc. (NASDAQ:AVTX) with a Buy rating and a price target of $35. According to the firm, the company is a “cleaner, single-asset immunology story” following the positive Phase 2 data […]
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State St
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.
Avalo shares spike on skin drug data; BioNTech to cut staff
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.